Brought to you by 
Ligand monetizes Promacta royalties through $827mm transaction with Royalty Pharma
Mar 2019
Executive Summary
Ligand Pharmaceuticals Inc. agreed to sell Royalty Pharma the intellectual property rights, including the royalty stream on worldwide net sales, to Promacta (eltrombopag) for $827mm in cash.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Transgenics
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ligand monetizes Promacta royalties through $827mm transaction with Royalty Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice